Previous Close | 10.48 |
Open | 10.34 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 10.34 - 10.62 |
52 Week Range | 3.84 - 12.50 |
Volume | |
Avg. Volume | 1,224 |
Market Cap | 200.553M |
Beta (5Y Monthly) | 0.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy